CN1561997A - Medicinal composition having anti-inflammation and anti-infection function - Google Patents
Medicinal composition having anti-inflammation and anti-infection function Download PDFInfo
- Publication number
- CN1561997A CN1561997A CN 200410022355 CN200410022355A CN1561997A CN 1561997 A CN1561997 A CN 1561997A CN 200410022355 CN200410022355 CN 200410022355 CN 200410022355 A CN200410022355 A CN 200410022355A CN 1561997 A CN1561997 A CN 1561997A
- Authority
- CN
- China
- Prior art keywords
- baicalin
- andrographolide
- medicine
- ingredient
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composite medicine for preventing and treating infection and inflammation is prepared from scutellarin, andrographolide and pharmacologically acceptable additives.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition with infection and antiinflammatory action.
Background technology
In natural drug, Radix Scutellariae is the Chinese medicine simply with heat clearing away, pathogenic fire purging, detoxicating functions.There are some researches show, heat clearing away in the natural drug Radix Scutellariae, pathogenic fire purging, the main effective ingredient of antidotal are flavone compounds such as baicalin, wogonoside, baicalin (aglycon), wogonin, and the effect of noroxylin is stronger than its glycosides, and baicalin is that antioxidation is the strongest in above 4 kinds of flavone, and result of study shows that may encircle last 3 vicinal hydroxyl groups with A in its structure has substantial connection.The structure of baicalin is as shown in the formula shown in (I).Effects such as the main pharmacodynamics effect of baicalin has the reaction of anti-bacteria and anti-virus, inflammation-inhibiting, removes free radical and antioxidation, anticoagulation and antithrombotic formation, carcinogenesis, protects the liver, function of gallbladder promoting and diuresis.
Herba Andrographis also is Chinese crude drug commonly used simply, can have heat-clearing and toxic substances removing, removing heat from blood, and the repercussive effect is usually used in cold, fever, laryngopharynx swelling and pain, diseases such as aphtha of the mouth and tongue.Wherein have heat-clearing and toxic substances removing, removing heat from blood, the main effective ingredient of detumescence effect is an andrographolide, structure is as shown in the formula shown in (II).It is widely used clinically, as andrographolide dispersed tablet, andrographolide capsule etc.
Because to having caused showing great attention to and paying attention to of the world of medicine as spreading of many traditional antibiotic resistant such as penicillin, amoxicillin, zinacef, the appearance of a large amount of appearance of multi-drug resistant bacterial strain and new virus makes intractable infection more and more common.Meanwhile, and the compositions of the compatibility of natural drugs such as traditional Chinese herbal medicine or effective ingredient also is difficult for producing drug resistance owing to often can have the effect of complementary and Synergistic, thereby the excavation and the research of natural drug is come into one's own day by day.Comprising to Radix Scutellariae and Herba Andrographis in the effect of antibiotic and anti-virus aspect and the research of effect.At present, traditional traditional Chinese compound medicine is processed into by the crude extract of natural medicinal raw material, as " compound Radix Scutellariae sheet ", " lotus sesame antiphlogistic capsule " etc., the volume and the dose of pharmaceutical preparation have been increased, the effective ingredient complexity, difficult quality control is said in a sense because effective ingredient can not fully discharge, absorb the waste that not exclusively causes medicinal raw material, and influence the performance of curative effect of medication.For this reason, publication number is that the Chinese patent literature of CN 1266699A had once reported with baicalin and andrographolide to be that effective medicinal ingredient is combined into the medicine with infection and antipyretic effect.
Summary of the invention
At above-mentioned situation, the purpose of this invention is to provide a kind of composition medicine with infection and antiinflammatory action more simple, that combine by the effective component extracts of the effective ingredient of natural medicinal raw material or its medicinal raw material, make that its effective ingredient is clear, content is high, quality controllable, dose is little, determined curative effect have better infection and antiphlogistic effects, and side effect is little.On this basis, the present invention further also will provide the medicine that has the operational dosage forms such as oral type, aerosol type and collunarium type of infection and anti-inflammatory efficacy effect with it as effective medicinal ingredient.
The present invention has the pharmaceutical composition of infection and antiinflammatory action, is 1/0.2～1/2 to form effective medicinal ingredient by baicalin and andrographolide with weight ratio, forms jointly with the auxiliary adding ingredient of acceptable in the medicine.Result of the test shows, in said this drug effect medicinal ingredient, the outstanding so that weight ratio of baicalin and andrographolide is 1/0.5～1/1 scope for better.
Above-mentioned effective medicinal ingredient baicalin suc as formula structure shown in (I) is yellow acicular crystal, and fusing point is 268～272 ℃ (methanol).This composition can obtain by full chemosynthesis mode, or is obtained through chemical improvement and/or after modifying by other related compound, for example can obtain corresponding baicalin after being hydrolyzed according to a conventional method by baicalin.In addition, can also adopt at present more simple mode commonly used, by natural medicinal raw material---can comprise the medicinal raw material Radix Scutellariae of general common direct employing, and other natural medicinal raw material that equally also contains the baicalin composition, as and the multiple natural medicinal raw materials such as leaf of the seed of the Ye Hegen of head grass, Bignoniaceae plant Semen Oroxyli and peel of stem, Plantaginaceae plant Big Semen Plantaginis, through extract with separate after obtain.Once reported at " some new development of Radix Scutellariae research " (" Chinese Pharmaceutical Journal " 2001,36 (11)) as people such as Hu Shilin, and adopted supercritical extraction method can reach 8.6mg/g by the baicalin yield that Radix Scutellariae obtains, higher by 51% than the 5.7mg/g of conventional method.When adopting the baicalin composition that obtains with the raw extract mode by crude drug, except that the required single form neat compounds that can adopt after being further purified, also can adopt also contain simultaneously mainly be present in its extract as wogonin, oroxylin A, can add baicalin, 7-methoxyl group baicalin and other compositions such as flavone aglycone chemical compound, and the extraction mixture of other impurity component that allow to exist.Result of the test shows, in aforementioned pharmaceutical compositions of the present invention, adopts the Radix Scutellariae total glucosides unit with weight 〉=70% that contains baicalin to replace, and generally can tangible influence or change do not arranged to its infection and antiinflammatory action.
As effective medicinal ingredient andrographolide of above-mentioned formula (II) structure is colourless square, prismatic or flaky crystal (ethanol or methanol), and fusing point is 230～231 ℃.Similar with baicalin, this andrographolide as effective medicinal ingredient equally both can be by the mode of full chemosynthesis, or obtain by the approach of other related compound through chemical improvement and/or modification, also can adopt by the Herba Andrographis of natural medicinal raw material through ethanol extraction with separate after obtain.Simultaneously, can also replace with the ethanol extraction that obtains by the Herba Andrographis raw material of the andrographolide that contains the significant proportion amount.When its ethanol extraction of direct use is replaced, this extract normally comprises this lactone at interior total andrographolides, as long as under the contained therein prerequisite that can not have a negative impact as other composition of impurity to the effect of effective ingredient in the said medicine of the present invention, according to the requirement and the allowed band of different preparations, and the chemical compound of single respective pure form is used in nonessential requirement and allow these impurity components to exist simultaneously with suitable form and/or ratio.
Therefore, for said two effective medicinal ingredients in the application's aforementioned pharmaceutical compositions, except that adopting the composition form of its single neat compounds respectively, according to the different needs in its source, mode and/or different preparation and the process thereof, can allow also to contain simultaneously other unavoidable impurity, complementary adding ingredient or can not cause adverse effect and/or interferential composition the drug action of said effective ingredient.
With effective medicinal ingredient of above-mentioned composition form, auxiliary adding ingredient combination such as corresponding pharmaceutic adjuvant with acceptable in the medicine or carrier, and, can become corresponding oral type pharmaceutical preparation by corresponding pharmaceutical methods processing.As, tablet, controlled release agent, drop pill, granule, capsule, micropill etc.For example, with can received disintegrating agent in oral formulations, after auxiliary interpolation composition that excipient, lubricant, binding agent, filler etc. are commonly used mixes, handle by corresponding common process method, promptly may be made in the oral drugs of the solid preparation forms such as slow releasing agent, controlled release agent of tablet, pill, capsule or appropriate format; Mix with the surfactants of using always such as solubilizing agent, emulsifying agent, wetting agent, foaming or defoamer, diluent, antiseptic, stabilizing agent, correctives, thickening agent etc., handle by corresponding common process method, promptly may be made in corresponding spray or nasal drop medicine.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But the scope that should at this point not be interpreted as the above-mentioned theme of the present invention only limits to following example.Do not breaking away under the above-mentioned technological thought situation of the present invention, all various modifications, replacement or changes of making according to ordinary skill knowledge and customary means include within the scope of the invention.
The specific embodiment
Embodiment 1:
Get baicalin 1000g, andrographolide 1000g respectively, add supplementary product starch 1000g, mix homogeneously is granulated, and suppresses 10000, promptly gets tablet of the present invention.
Embodiment 2:
Get baicalin 500g, andrographolide 250g respectively, add the ethanol heating for dissolving, join again in the PEG-6000 fused solution, fully stir and wave most ethanol, in the drop pill machine, make 10000 drop pill, promptly get pill-type medicine of the present invention.
Embodiment 3:
Get (baicalin weight content 〉=70%) 2000g of Radix Scutellariae total glucosides unit and andrographolide 500g, dry-pressing is granulated, and 10000 in dress glue capsule promptly gets capsule of the present invention.
Embodiment 4:
Get baicalin 50g and andrographolide 100g is standby after conventional micronization processes.Fabaceous lecithin 20g is mixed with (80 ℃) water, tween 80 and the glycerol 50ml of preheating, in high-speed tissue mashing machine, stir; Add Oleum Glycines 50g and above-mentioned baicalin, andrographolide micropowder, carry out high-speed stirred again; The water that adds same preheating changes the high pressure dispersing emulsification machine over to, homogenize to 500ml.Packing is put in the plastic soft bottle, and every 10ml is nasal drop of the present invention.Or put in the pressure vessel, add valve, sealing cap, be pressed into propellant, shake up, be spray of the present invention.
The medicine that with the foregoing description 2 baicalins/andrographolide is 2/1 form has carried out acute toxicity test as the test specimen medicine:
Get 20 of mices, once irritate stomach maximum dosage-feeding 19.04g/kg (be equivalent to intend clinical every day recommended dose 865 times).Visible one crosses inhibitory state such as property tachypnea, tired volt be moving less after the administration, infer with irritate the stomach volume excessive due to.Observed 7 days continuously later on, the outward appearance of animal, behavioral activity, the mental status, defecation and color thereof, quilt hair, the colour of skin, breathing, nose, eye, oral secretion etc. there is no unusual, and eye anatomy is not seen obvious pathological change during off-test.The toxicity performance judges that this product belongs to no overt toxicity medicine after acute toxicity institute's amount of reagent of said medicine and the administration.
With the above-mentioned pharmaceutical composition of effective medicinal ingredient of forming by different proportion by baicalin/andrographolide of the present invention as trial drug (compositions (I)), carried out the part pharmacodynamics test of relevant antibiotic, antiviral, antiinflammatory action, and described with aforementioned documents with baicalin and andrographolide antibiotic, antiviral, antiinflammatory action contrast test as the control drug (compositions (II)) of drug effect medicinal ingredient.
One, antibiotic, antivirus action
The ratio (weight) of the baicalin/andrographolide in the trial drug compositions of selecting in the experiment medicine of the present invention (I) is respectively: 10/0,10/2,10/5,10/10,10/20,0/10,10/0 and 0/10 liang of group wherein only is equivalent to respectively with single baicalin and andrographolide as the effective medicine of medicinal ingredient; Baicalin in the documents control drug compositions (II)/andrographolide ratio is 10/2 and 10/5.
1, antibacterial action
Adopt (meat soup) doubling dilution will be subjected to the reagent thing to carry out quantitatively inoculating the detection bacterium again after a series of doubling dilution, measure the minimum inhibitory concentration (MIC) of each testing sample, adopt viable bacteria counting method to measure minimum bactericidal concentration (MBC).Observe after hatching 18-24h for 35 ℃, suppress to detect the lowest concentration of drug of bacterial context eye visible growth for measuring medicine to detecting the minimum inhibitory concentration (MIC) of bacterium, to not see that again bacterial growth pipe culture fluid 0.1ml transferred species is in no medicine agar half ware surface, 35 ℃ are continued to cultivate 18h, and the medicine least concentration that does not still have bacterial growth or clump count＜5 CFU/ml is minimum bactericidal concentration (MBC).The MIC and the MBC comparative test result of medicine baicalin of the present invention/andrographolide compositions (10/2,10/5,10/10,10/20) and two single medicinal ingredient groups (10/0,0/10) wherein and control drug baicalin/andrographolide compositions (10/2,10/5) are as shown in table 1.
The result of the test of table 1 clearlys show, the drug study samples of the present invention (baicalin/andrographolide 10/2,10/5,10/10,10/20) formed of two of form kinds of active ingredient in varing proportions, have antibiotic and bactericidal action to test strain, all be better than the baicalin (10/0) and andrographolide (0/10) group of single active ingredient.And the antibiotic and bactericidal action of the invention described above medicine also obviously is better than baicalin/andrographolide (10/2,10/5) group of control drug compositions (II).The result of table 1 also demonstrates, the antibacterial activity in vitro of baicalin/andrographolide (10/2,10/5,10/10,10/20) different proportion form laboratory sample is similar substantially in the pharmaceutical composition of the present invention (I), but wherein excellent slightly with baicalin/andrographolide 10/5.
2, antivirus action
Adopt histiocyte median infective dose (TCID
50) method, according to the inhibition effect of medicine pair cell pathological changes, with the antiviral effect of confirmed test medicine to Adv3 and RSV.
(1) medicinal liquid preparation: with RPMI-1640 trial drug is carried out the two-fold dilution, its liquor strength is respectively 2.5mg/ml, 1.25mg/ml, 0.625mg/ml, 0.3125mg/ml.The concentration of virazole is respectively 0.062,0.031, and 0.015 and 0.008mg/ml.
(2) to the maximal non-toxic concentration determination of Vero cell and Hep-2 cell: in the Vero cell monolayer of 96 porocyte culture plates and Hep-2 cell monolayer, add the trial drug of variable concentrations respectively, put 37 ℃ and 5%CO
2In the incubator 96 hours, the observation of cell pathological changes was measured its maximal non-toxic concentration to Vero cell and Hep-2 cell monolayer.
(3) Adv3 virus is caused the cytopathic inhibition test of Vero: in the Vero cell monolayer of 96 porocyte culture plates, Adv3 10TCID is infected in every hole
50(7LgTCID
50) viral liquid, hypsokinesis in the 2 hours venom of preventing or cure a disease adds the trial drug or the virazole of variable concentrations again in every hole, cultivate observation of cell pathological changes after 96 hours.
(4) RSV virus is caused the cytopathic inhibition test of Hep-2: in the Hep-2 cell monolayer of 96 porocyte culture plates, RSV 10TCID is infected in every hole
50(6LgTCID
50) viral liquid, hypsokinesis in the 2 hours venom of preventing or cure a disease adds the trial drug or the virazole of variable concentrations again in every hole, cultivate observation of cell pathological changes after 96 hours.
(5) experimental result
1. each trial drug is measured through the CPE method the maximal non-toxic concentration of Vero cell, and all less than 5.0mg/ml, in formal drug test, then the medicine of employing＜5.0mg/ml carries out the extracorporeal antivirus effect test.
The different proportioning compositions of table 1 minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) (unit: mg/ml)
| Experimental strain | Pharmaceutical composition of the present invention (I) (baicalin/andrographolide) | Control drug compositions (II) (baicalin/andrographolide) | ||||||||||||||
| ??????10/0 | ???????10/2 | ???????10/5 | ???????10/10 | ??????10/20 | ???????0/10 | ??????10/2 | ?????????10/5 | |||||||||
| ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | ??MIC | ??MBC | |
| Staphylococcus aureus | ??0.39 | ??0.78 | ??0.39 | ??0.78 | ??0.20 | ??0.39 | ??0.20 | ??0.78 | ??0.39 | ??1.56 | ??0.78 | ??3.12 | ??1.56 | ??3.12 | ??0.78 | ??3.12 |
| Aerobacteria | ??0.78 | ??3.12 | ??0.78 | ??1.56 | ??0.78 | ??1.56 | ??0.78 | ??1.56 | ??0.78 | ??1.56 | ??1.56 | ??3.12 | ??3.12 | ??6.25 | ??3.12 | ??6.25 |
| Bacillus pyocyaneus | ??3.12 | ??6.25 | ??1.56 | ??3.12 | ??1.56 | ??3.12 | ??1.56 | ??3.12 | ??1.56 | ??6.25 | ??3.12 | ??12.5 | ??6.25 | ??12.5 | ??3.12 | ??12.5 |
| Streptococcus pneumoniae | ??0.78 | ??3.12 | ??0.39 | ??0.78 | ??0.39 | ??0.78 | ??0.39 | ??1.56 | ??0.78 | ??3.12 | ??1.56 | ??6.25 | ??3.12 | ??6.25 | ??1.56 | ??3.12 |
| Hemophilus influenza | ??0.78 | ??1.56 | ??0.39 | ??1.56 | ??0.20 | ??0.39 | ??0.39 | ??1.56 | ??0.39 | ??3.12 | ??1.56 | ??3.12 | ??3.12 | ??6.25 | ??3.12 | ??6.25 |
| Escherichia coli | ??1.56 | ??3.12 | ??1.56 | ??3.12 | ??0.39 | ??1.56 | ??0.78 | ??1.56 | ??0.78 | ??3.12 | ??3.12 | ??6.25 | ??6.25 | ??25 | ??6.25 | ??25 |
| Klebsiella Pneumoniae | ??0.78 | ??3.12 | ??0.39 | ??0.78 | ??0.20 | ??0.78 | ??0.39 | ??0.78 | ??0.39 | ??1.56 | ??1.56 | ??6.25 | ??3.12 | ??6.25 | ??1.56 | ??3.12 |
| Pseudomonas aeruginosa | ??0.78 | ??1.56 | ??0.39 | ??0.78 | ??0.20 | ??0.39 | ??0.20 | ??0.78 | ??0.78 | ??1.56 | ??1.56 | ??3.12 | ??3.12 | ??6.25 | ??3.12 | ??6.25 |
| Streptococcus hemolyticus | ??1.56 | ??3.12 | ??0.78 | ??1.56 | ??0.39 | ??1.56 | ??0.78 | ??1.56 | ??1.56 | ??3.12 | ??3.12 | ??6.25 | ??6.25 | ??12.5 | ??3.12 | ??6.25 |
| The Ke Shi pneumobacillus | ??3.12 | ??6.25 | ??1.56 | ??3.12 | ??0.78 | ??1.56 | ??0.78 | ??3.12 | ??1.56 | ??6.25 | ??6.25 | ??12.5 | ??12.5 | ??25 | ??6.25 | ??12.5 |
| Bacillus cloacae | ??3.12 | ??6.25 | ??1.56 | ??3.12 | ??0.78 | ??3.12 | ??0.78 | ??3.12 | ??1.56 | ??6.25 | ??3.12 | ??12.5 | ??6.25 | ??25 | ??3.12 | ??12.5 |
2. each trial drug causes the cytopathic inhibitory action of Vero to Adv3 virus, and RSV virus is caused the cytopathic inhibitory action of Hep-2.Result of the test is as shown in table 2.
The different trial drug extracorporeal antivirus effect effects of forming of table 2
| Medicine | Strain | Drug level (mg/ml) | Virus control | The cell contrast | ||||
| ????2.5 | ??1.25 | ????0.625 | ??0.3125 | |||||
| Compositions (I) | ??10/0 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????1+ ????1+ | ????2+ ????2+ | ????4+ ????4+ | ??- ??- |
| ??10/2 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????- ????- | ????1+ ????1+ | ????4+ ????4+ | ??- ??- | |
| ??10/5 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????- ????- | ????1+ ????1+ | ????4+ ????4+ | ??- ??- | |
| ??10/10 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????- ????- | ????1+ ????1+ | ????4+ ????4+ | ??- ??- | |
| ??10/20 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????- ????- | ????2+ ????2+ | ????4+ ????4+ | ??- ??- | |
| ??0/10 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????2+ ????2+ | ????3+ ????3+ | ????4+ ????4+ | ??- ??- | |
| Compositions (II) | ??10/2 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????2+ ????2+ | ????3+ ????3+ | ????4+ ????4+ | ??- ??- |
| ??10/5 | ??Adv3 ??RSV | ????- ????- | ??- ??- | ????2+ ????2+ | ????3+ ????3+ | ????4+ ????4+ | ??- ??- | |
| Control drug (virazole) | ????0.062 | ??0.0031 | ????0.015 | ????0.008 | ||||
| ??Adv3 ??RSV | ????- ????- | ??- ??- | ????- ????2+ | ????2+ ????3+ | ????4+ ????4+ | ??- ??- | ||
Annotate: "-" expression cell does not have pathological changes;
" 1+ " about 25% cell generation pathological changes, " 2+ " about 50% cell generation pathological changes, " 3+ " about 75% cell generation pathological changes,
" 4+ " about 100% cell generation pathological changes.
By table 2 result as can be seen: the baicalin/andrographolide compositions (10/2,10/5,10/10,10/20) of each proportion of composing of pharmaceutical composition of the present invention (I) is when 0.625mg/ml concentration, Adv3 and RSV are had significant inhibitory effect, and be better than the baicalin/andrographolide compositions (10/2,10/5) of baicalin (10/0), andrographolide (0/10) and the reference composition (II) of single form.Effective inhibition concentration of baicalin and andrographolide is 1.25mg/ml.
3, antiinflammatory action
On the basis of above-mentioned result of the test, be the experimentation that trial drug has further carried out following antiinflammatory action with the pharmaceutical composition of the present invention (I) of baicalin/andrographolide (2/1) form.
(1) 100 of the male mices that influence to the mice granuloma induced by implantation of cotton pellets are divided into 10 groups at random, under pentobarbital sodium (40mg/kg) anesthesia, and in the sterilization down of each Mus right side axillary fossa, otch 0.3cm, subcutaneous implantation 10mg sterilization cotton balls is sewed up sterilization.After this respectively organize the ig administration every day, once a day, continuous 14d.24h wins and is with the cotton balls of granulation tissue to weigh after 60 ℃ of 18h dryings after the last administration, deducts cotton balls weight (10mg) with the cotton balls weight of being with granulation, is granulation tissue weight, and the result is as shown in table 3.By the visible drug test sample baicalin of the present invention of table 3/andrographolide compositions (10/5), large and small dosage group all has the obvious suppression effect to cotton balls granulation tissue weight, and is better than the corresponding dosage group of baicalin (10/0), andrographolide (0/10) and the baicalin/andrographolide compositions (10/5) of independent type of service.
(2) 100 of the mices that influence to the mouse peritoneal capillary permeability are divided into 10 groups at random, behind the ig administration 1h, tail vein injection 1% azovan blue 0.1ml/, and lumbar injection 0.6% acetic acid 0.2ml/ simultaneously, behind the 20min, draw cervical vertebra to put to death animal, cut off the abdominal cavity, with 5ml distilled water flushing abdominal cavity for several times, draw the centrifugal 5min of abdominal cavity eluate, 590nm measures absorption value (OD), and the result is as shown in table 3.By the visible drug test sample baicalin of the present invention of table 3/andrographolide compositions (10/5), large and small dosage group all can obviously suppress the mouse peritoneal capillary permeability, and is better than the corresponding dosage group of baicalin (10/0), andrographolide (0/10) and the baicalin/andrographolide compositions (10/5) of independent type of service.
Table 3 trial drug is to the influence of mice granuloma induced by implantation of cotton pellets and abdominal cavity capillary permeability
Group dosage granuloma induced by implantation of cotton pellets dry weight suppression ratio optical density value
(g/kg)??????(mg/10mg)??????(％)
Matched group-11.93 ± 2.14 0.567 ± 0.126
Dexamethasone 0.0045 8.81 ± 1.12
*26.2 0.373 ± 0.124
*
1??????????8.97±2.05
**??24.8????????0.397±0.138
*
Baicalin/andrographolide
0.5????????9.44±2.17
*???20.9????????0.431±0.125
*
1??????????9.28±2.24
*???22.2????????0.415±0.102
*
Baicalin/andrographolide
0.5????????9.86±2.26?????17.4????????0.485±0.131
1??????????9.22±2.43
*???22.7????????0.425±0.127
*
Baicalin
0.5????????9.95±2.51?????16.6????????0.491±0.143
1??????????9.30±2.06
*???22.0????????0.406±0.122
*
Andrographolide
0.5????????9.84±2.37?????17.5????????0.482±0.136
Compare with matched group
*P＜0.05,
*P＜0.01
Above-mentioned result of the test clearlys show, adopt that the present invention proposes with baicalin and andrographolide pharmaceutical composition as effective medicinal ingredient, comprehensive antibiotic, antiviral and antiinflammatory action aspect can have the obvious synergistic effect, its result not only is better than the wherein independent use of each effective medicinal ingredient, also obviously being better than currently reported employing is the compositions of effective medicinal ingredient by baicalin and andrographolide, be the more significantly pharmaceutical composition of the further optimization of superiority that has that obtains on its basis, have gratifying DEVELOPMENT PROSPECT and value.
Claims (5)
1. the pharmaceutical composition that has infection and antiinflammatory action is characterized in that being made up of as the auxiliary adding ingredient of acceptable in effective medicinal ingredient and the medicine with weight ratio 1/0.2～1/2 baicalin/andrographolide.
2. the pharmaceutical composition with infection and antiinflammatory action as claimed in claim 1 is characterized in that the baicalin in said effective medicinal ingredient and the weight ratio of andrographolide are 1/0.5～1/1.
3. the pharmaceutical composition with infection and antiinflammatory action as claimed in claim 1 is characterized in that the Radix Scutellariae total glucosides unit that said effective medicinal ingredient is the weight content of baicalin 〉=70%.
4. as the described pharmaceutical composition of one of claim 1 to 3, it is characterized in that forming oral type pharmaceutical preparation by the auxiliary adding ingredient of acceptable in said effective medicinal ingredient and the medicine with infection and antiinflammatory action.
5. as the described pharmaceutical composition of one of claim 1 to 3, it is characterized in that forming spray and nasal drop by the auxiliary adding ingredient of acceptable in said effective medicinal ingredient and the medicine with infection and antiinflammatory action.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022355 CN1234355C (en) | 2004-04-20 | 2004-04-20 | Medicinal composition having anti-inflammation and anti-infection function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022355 CN1234355C (en) | 2004-04-20 | 2004-04-20 | Medicinal composition having anti-inflammation and anti-infection function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1561997A true CN1561997A (en) | 2005-01-12 |
| CN1234355C CN1234355C (en) | 2006-01-04 |
Family
ID=34480057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022355 Expired - Fee Related CN1234355C (en) | 2004-04-20 | 2004-04-20 | Medicinal composition having anti-inflammation and anti-infection function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234355C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340239C (en) * | 2005-02-02 | 2007-10-03 | 严洁 | Andrographolide dispersing tablets |
| CN107648311A (en) * | 2017-08-30 | 2018-02-02 | 四川省中医药科学院 | With antiviral and composition and medicine of antiinflammatory action |
-
2004
- 2004-04-20 CN CN 200410022355 patent/CN1234355C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340239C (en) * | 2005-02-02 | 2007-10-03 | 严洁 | Andrographolide dispersing tablets |
| CN107648311A (en) * | 2017-08-30 | 2018-02-02 | 四川省中医药科学院 | With antiviral and composition and medicine of antiinflammatory action |
| CN107648311B (en) * | 2017-08-30 | 2020-07-10 | 四川省中医药科学院 | Composition and medicine with antiviral and antiinflammatory effects |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234355C (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN1857416A (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away head and toxic materials and its preparing method and application | |
| CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
| CA3167551A1 (en) | Use of pharmaceutical composition in preparing antibacterial drug | |
| CN1268368C (en) | Anti-virus houttuynia cordate medicine and its preparation | |
| CN1234355C (en) | Medicinal composition having anti-inflammation and anti-infection function | |
| CN1943734A (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN1261143C (en) | Separating preparation process of effective part and active component of influenza virus resisting medicine | |
| CN1164267C (en) | Chlorogenic acid and isochlorogenic acid composition and medical use thereof | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN102600120B (en) | Application of cinnamic acid in preparation of drugs for preventing and treating livestock and poultry virus infection | |
| CN100546573C (en) | A kind of anti-infective medicament composition and preparation method thereof | |
| CN101062021A (en) | Diarrhea treating medical composition | |
| CN101073625A (en) | Medicinal composition with anti-infective and anti-inflammatory functions | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1686091A (en) | Composition of aiphenyl hepatanone compound and its use | |
| CN1966051A (en) | Antivirus medicament | |
| CN110368429A (en) | Prevent and treat the Chinese medicine composition and preparation method thereof that bacillary enterogastritis draws dysentery | |
| CN1294910C (en) | Medicinal composition having antiseptic and anti-inflammatory function | |
| CN1202101C (en) | Medicinal compound with anti-infection, anti-inflammatory and antipyretic, and improving immunity function | |
| CN101926846A (en) | Medicinal composition for treating pullorum disease and preparation method thereof | |
| CN114209732B (en) | Medicine for preventing and treating nocardiosis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |